The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a significant substantial loss in body weight and benefit metabolic markers